Among CML patients, 95% have a distinctive cytogenetic abnormality, the Philadelphia chromosome (Ph1), which results in a fused BCR/ABL gene and in the production of an abnormal tyrosine kinase protein that causes the disease. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.